Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

被引：0
|
作者：
Santoro, Nanette [1 ]
Neal-Perry, Genevieve [2 ]
Stute, Petra [3 ]
Blogg, Martin [4 ]
Mancuso, Shayna [5 ]
Morga, Antonia [4 ]
Ottery, Faith D. [5 ]
Siddiqui, Emad [4 ]
机构：
[1] Univ Colorado, Sch Med, Aurora, CO USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Inselspital Bern, Bern, Switzerland
[4] Astellas Pharma Europe Ltd, Addlestone, Surrey, England
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
S-8
引用
收藏
页码：1259 / 1259
页数：1
相关论文
共 50 条
  • [41] Effect of continuous positive airway pressure in very elderly with moderate-to-severe obstructive sleep apnea pooled results from two multicenter randomized controlled trials
    Martinez-Garcia, M. A.
    Oscullo, G.
    Ponce, S.
    Pastor, E.
    Orosa, B.
    Catalan, P.
    Martinez, A.
    Hernandez, L.
    Muriel, A.
    Chiner, E.
    Vigil, L.
    Carmona, C.
    Mayos, M.
    Garcia-Ortega, A.
    Gomez-Olivas, J. D.
    Beauperthuy, T.
    Bekki, A.
    Gozal, D.
    SLEEP MEDICINE, 2022, 89 : 71 - 77
  • [42] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Eric L. Simpson
    Dermatology and Therapy, 2017, 7 : 243 - 248
  • [43] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Simpson, Eric L.
    DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
  • [44] A Phase 3, randomized, placebo-controlled, 12-week, double-blind study, plus a non-controlled extension treatment period, to assess efficacy and safety of fezolinetant, a neurokin-3 receptor antagonist, in women with moderate-to-severe vasomotor symptoms associated with menopause
    Johnson, Kimball
    Lademacher, Christopher
    Nappi, Rossella E.
    Neal-Perry, Genevieve
    Shapiro, Marla
    Stute, Petra
    Thurston, Rebecca C.
    Wolfman, Wendy
    English, Marci
    Franklin, Catherine
    Lee, Misun
    Santoro, Nanette
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2021, 28 (12): : 1450 - 1450
  • [45] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
    Merola, Joseph F.
    Elewski, Boni
    Tatulych, Svitlana
    Lan, Shuping
    Tallman, Anna
    Kaur, Mandeep
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 79 - +
  • [46] Improvements in health-related quality of life and symptoms of depression with tofacitinib: Results from two randomized phase 3 studies in patients with moderate to severe psoriasis
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Bundy, Christine
    Korman, Neil J.
    Lan, Shuping
    Robertson, Deborah
    Tatulych, Svitlana
    Tallman, Anna
    Kaur, Mandeep
    Mamolo, Carla
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [47] Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Lebwohl, Mark
    Green, Lawrence
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB167 - AB167
  • [48] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [49] Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies
    Simpson, Eric L.
    Boguniewicz, Mark
    Thaci, Diamant
    Misery, Laurent
    Silverberg, Jonathan I.
    Beck, Lisa A.
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Szepietowski, Jacek C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB121 - AB121
  • [50] Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies
    Mukherjee, A.
    Tsuchiwata, S.
    Deng, C.
    Vong, C.
    Xie, R.
    Martin, S. W.
    Yu, D.
    Woodworth, D.
    Niezychowski, W.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S73 - S74
12345